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Abstract
Background: Alveolar osteitis (AO) is a commonly seen post-operative complication during the wound-healing period 
after permanent tooth extraction or surgical removal of impacted third molar teeth.
Objectives: The aim of this clinical study was to evaluate the effects of administration of the topical hemostatic agent 
Ankaferd Blood Stopper (ABS) into the socket on AO formation after impacted mandibular third molar extraction.
Patients and Methods: Bilaterally, 100 half-impacted mandibular third molars were extracted in 50 patients. Then, 
1.0 mL ABS was administered to achieve hemostasis in one half of the sockets and as a control, the other half was 
irrigated with 1.0 mL physiological serum after surgery.
Results: There was no statistically significant difference in terms of AO formation (P > 0.05) between the extraction 
sites. However, the postoperative pain in ABS administration sites was higher than in the other sites for the first 2 days 
after surgery (P < 0.05).
Conclusions: The results showed that ABS administration did not increase the incidence of AO formation. Thus, ABS 
can be used safely for hemostasis after impacted mandibular third molar surgery.
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Introduction
Alveolar osteitis (AO) is a commonly seen post‑operative 
complication[1‑4] during the wound‑healing period after 
permanent tooth extraction or surgical removal of impacted 
third molar teeth. AO is also known as dry socket, alveolitis 
sicca dolorosa, fibrinolytic alveolitis, alveolitis, localized osteitis, 
localized AO, septic socket, necrotic socket, and alveolalgia.[5‑11] 
First, in the literature, AO was called as “dry socket” and 
defined by Crawford[12] in 1896. Although “dry socket” is a 
generic term, “AO” is used more commonly today.[2,11,13,14]
The incidence of AO has been reported to be between 0.5% 
and 5% for routine tooth extractions[2,11,13,15‑18] and varies 
from 1% to 45% after the extraction of mandibular third 
molars.[2,11,13,18‑20] This rate can be approximately 10 times 
higher after surgical extractions when compared to normal 
tooth extractions.[13]
The exact etiology of AO is not well‑understood. Many 
concepts about AO are still debated by researchers. Many 
causes have been suggested for AO formation, including 
bacterial infection,[2,21‑23] and increased fibrinolytic 
activity.[11,23‑25] Birn[7] suggested that increased local 
Effects of the topical hemostatic agent Ankaferd 
Blood Stopper on the incidence of alveolar osteitis 
after surgical removal of an impacted mandibular 
third molar
M Tek, I Akkas, O Toptas, F Ozan, I Sener1, C Bereket1
Departments of Oral and Maxillofacial Surgery, Faculty of Dentistry, Abant Izzet Baysal University, Bolu, 1Ondokuz Mayis 
University, Samsun, Turkey





76 Nigerian Journal of Clinical Practice • Jan-Feb 2014 • Vol 17 • Issue 1
Tek, et al.: Effects of Ankaferd Blood Stopper on alveolar osteitis
fibrinolysis caused the disintegration of the blood clot in 
the socket as the etiologic reason for AO. The fibrinolysis 
is the result of plasminogen pathway activation, which 
can be accomplished through direct (physiological) or 
indirect (non‑physiological) activator substances. Direct 
activators are released after trauma to the alveolar bone 
cells. Indirect activators are produced by bacteria.
Many risk factors have been reported[10,11,13,14] to influence the 
formation of AO after surgical removal of impacted third molar 
teeth. In fact, AO can occur due to total loss, partial loss, or 
no formation of a blood clot in the bone socket in the early 
period after tooth extraction. Thus, the formation of a blood 
clot and prevention of blood clot disruption are important in 
preventing the development of AO in removed tooth sockets.
Ankaferd Blood Stopper (ABS; Ankaferd Health Products 
Ltd., Istanbul, Turkey) is a traditional folk medicinal plant 
extract product that has long been used in the traditional 
medicine as a topical hemostatic agent. In Turkey, ABS 
has been approved for the treatment of oral surgery 
bleeding and external source hemorrhages.[26‑29] ABS is a 
standardized mixture of the plants Thymus vulgaris (dried leaf), 
Glycyrrhiza glabra (dried leaf), Vitis vinifera (dried leaf), Alpinia 
officinarum (dried leaf), and Urtica dioica (dried root). ABS is 
an effective hemostatic agent that has therapeutic potential 
for the management of hemorrhage. The basic mechanism of 
action of the hemostatic effects of ABS is currently unknown. 
However, ABS has been shown to promote the formation 
of an encapsulated protein mesh, which acts as an anchor 
for erythrocyte aggregation, without significantly interfering 
with individual coagulation factors.[30] Specifically, the blood 
clot forming mechanism of ABS varies from the normal 
blood clot mechanism. In addition, ABS has effects on new 
bone formation, bacteria, the endothelium, blood cells, 
angiogenesis, cellular proliferation, vascular dynamics, and/or 
cellular mediators.[30‑35]
Clinical studies of hemostatic agents in terms of their 
effects on the incidence of AO after impacted mandibular 
third molar extraction have been reported.[36,37] Although 
ABS had some positive effects on new bone formation,[33] 
bacteria,[32] cytotoxicity,[38] and blood clot formation[30] 
during the wound‑healing period, the effects of ABS in 
AO formation have not been studied previously in removed 
impacted mandibular third molar sockets. The purpose of 
this clinical study was to investigate the effects of ABS 
administration on the incidence of AO formation after 
impacted mandibular third molar surgery.
Patients and Methods
This study followed the Declaration of Helsinki on medical 
protocols and ethics and the regional Ethical Review Board 
of Abant Izzet Baysal University approved the study. All 
patients were informed that they were to be included in 
the study before surgical treatment. The purpose, plan, 
procedure, and treatment were included in this information. 
All patients provided written informed consent before being 
included in the study.
In this prospective, randomized, blinded study, bilateral 
mandibular half‑impacted third molars of 50 patients, 
which were only partially covered with soft‑tissue, were in a 
vertical position, and posed similar difficulties for operation 
were removed. 35 of the patients were females and 15 were 
males. There were no symptoms of acute inflammation or 
infection in the surgical sites in any patient at the time of 
surgery. Some patients were smokers. None of the patients 
that were included in the sample was using antibiotics for 
any medical condition.
Conventional impacted third molar surgery procedures 
were performed in all patients. Surgical treatments were 
performed by the same experienced oral and maxillofacial 
surgeons in all 50 patients. Bilateral mandibular impacted 
third molars were removed at the same time and under local 
anesthesia, obtained by inferior alveolar, lingual, and long 
buccal nerve block, using 2 mL Maxicaine (Vem İlaç Sanayi 
ve Ticaret  Ltd.  ŞTİ., Ankara, Turkey;  80.0 mg  articain 
with 1:200 000 epinephrine) via a dental injector. The 
incision was performed with a #15 blade for the envelope 
flap. After a mucoperiosteal flap was raised, bilateral 
mandibular impacted third molars were removed during 
the same procedure. Then, in a consecutive manner, one of 
the bilateral mandibular impacted third molar sockets was 
irrigated with 1.0 mL of physiological serum using a dental 
injector and 1.0 mL of ABS was administered to achieve 
hemostasis in the other socket, also using a dental injector. 
The intra‑oral region was cleaned using a sterile suction 
tip. Within a few seconds, a blackish‑brown blood clot was 
formed in the socket that received ABS. Subsequently, these 
wounds were closed with 3.0 silk sutures, maintaining the 
blood clot in both sockets. No antibiotic was prescribed 
after surgery.
A visual analog scale (VAS) form was used daily to 
determine the degree of pain in the bilateral extraction 
sites in all patients. All patients were instructed to fill out 
the VAS form for 7 days and to return 1 week later for the 
removal of sutures and a follow‑up evaluation. If there was 
severe pain or discomfort in the wound area, or a bad taste 
or smell in the mouth, patients were encouraged to return 
sooner for their appointment.
The evaluation of all patients for AO was performed by the 
same surgeon who was not one of the operating surgeons. 
If the patient complained of severe pain in the wound area 
and if there was a loss of blood clot, necrotic debris, or 
exposed bone, clinically, AO was diagnosed. In addition, if 
there were signs of bacterial infection, such as swelling, pain, 
purulent drainage from the extraction site, and high body 
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temperature, a bacterial infection was diagnosed, clinically. 
In case, AO or bacterial infection, necessary therapy was 
made available.
Post‑operative AO formation in the physiological 
serum‑irrigated sites and ABS administration sites was 
compared statistically with the Chi‑squared test. Statistical 
analysis of the VAS values was conducted using the 
Mann‑Whitney U‑test.
Results
In this clinical study, bilateral mandibular impacted third 
molars were removed in 50 patients. The average age of 
the patients was 22.8 (range, 17‑41) years. Of the patients, 
70% were female, and 30% were male. Furthermore, 24% 
were smokers, and 8% were in their menstrual period. 
The overall average AO rate was 15/100 (15%). AO 
occurred in 8/50 ABS administration sites (16%) and in 
7/50 sites irrigated with the physiological serum (14%). 
There was no statistically significant difference between 
the sites (P > 0.05). VAS scores demonstrated that 
post‑operative pain was statistically significantly higher 
in the ABS administration socket sites than in the sites 
irrigated with physiological serum during the first 2 days 
after surgery (P < 0.05).
Discussion
ABS has positive effects on new bone formation,[33] 
bacteria,[32] cytotoxicity,[38] and blood clot formation[30,35] in 
the wound‑healing period. Based on this, we first determined 
the effects of ABS on AO formation in removed impacted 
mandibular third molar sockets in this clinical study.
AO consists of a breakdown in the normal healing 
mechanism in the sockets. The incidence of AO has 
been previously reported in the range 1‑45% after the 
extraction of mandibular third molars.[2,11,13,18‑20] In this 
study, the overall incidence of AO was 15% in 100 impacted 
mandibular third molar sites. The incidence of AO was 16% 
in the ABS administration sockets and 14% in the control 
sockets. Results in both sites were almost equal. Our findings 
are similar to an other reports[2,11,13] in terms of the incidence 
of AO formation in both sites.
True AO is characterized by the partial or total premature 
loss of the blood clot that forms in the interior of the 
alveolus after extraction. This must be distinguished from 
other conditions, such as hypovascularization of the alveolar 
bone, caused by vascular and hematological impairment, 
osteonecrosis induced by radiotherapy, osteopetrosis,[39] 
Paget’s disease, and cement‑osseous dysplasia, in which 
the clot forms in the interior of the alveolus.[13,39,40] In our 
study, in order to increase the reliability of the outcomes, in 
the selection of the sample, it was ensured that none of the 
above mentioned conditions existed in any of our patients.
Many techniques and methods that can assist in the 
prevention of AO formation have been proposed.[11,13] These 
include use of chlorhexidine mouthwash,[22,41,42] the placement 
of medicated packing into the extraction sockets,[43] the use 
of different patterns of antibiotics[44‑46] (systemic antibiotic, 
topical antibiotic), use of para‑hydroxybenzoic acid,[47] and 
the use of polylactic acid.[37,48,49] Further, for the reliability 
of outcomes, in this study no other method or technique 
was used to prevent the formation of AO.
Treatment of patients with AO is palliative. Specialists first 
think of prompt relief from the severe pain until normal 
healing begins in removed tooth sockets for AO treatment. 
In general, AO healing occurs within 1‑4 weeks after the 
initial surgery.[11,13,14,43,50‑52] Many treatment modalities have 
been presented in the literature such as using the low‑level 
laser therapy,[52] placing SaliCept patches,[50,52] Alvogyl,[52,53] 
medicated packing,[43] or lidocaine jelly.[51] Other than these, 
cleaning and irrigation of the tooth socket are important 
to remove any debris and bacteria from the extraction site 
in AO treatment.[51,52] In our study, the post‑operative 
treatment of the formation of AO was carried out using the 
proper medical treatment.
There are many risk factors associated with an increased 
incidence of AO, which include frequent changing of 
pressure‑dressing gauze and frequent mouth rinsing,[54] 
surgical trauma and difficulty in surgery,[7,8,11,37,55] 
bacterial involvement,[11,56‑58] smoking,[11,59,60] inadequate 
wound irrigation,[61] an inexperienced surgeon,[9,24,62] 
gender (female),[8,11,63] increased age,[8,11,63] use of oral 
contraceptives[11,41,64] and timing in the menstrual 
cycle,[64] flap design/suturing,[11,65] vasoconstrictors in 
local anesthetics,[11] saliva,[11,66] single extraction (versus 
multiple),[14] and bone/root fragments.[7,11,13] Thus, to 
eliminate these risk factors and to increase the reliability 
of the results, the procedures presented below were taken 
into consideration in the planning stage of this research as 
standard and were applied to all patients:
1.  Conventional impacted third molar surgery procedures 
were performed in all 50 patients by four oral and 
maxillofacial surgeons who had similar professional 
experience in order to minimize any possible after surgery 
complications that would otherwise have been caused 
by surgeons with different professional experience
2.  Both bilateral mandibular half‑impacted third molars 
of the patients were removed on the same day at the 
same time
3.  There were no symptoms such as acute inflammation 
or acute infection in any of the surgical sites.
4.  No patient was using antibiotics for any medical 
condition prior to the surgery and no patient was 
prescribed antibiotics after surgery as the use of 
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antibiotics affect the outcome of the treatment.
5.  All bilateral mandibular half‑impacted third molars of 
the patients were only partially covered with soft‑tissue, 
were in a vertical position, and posed similar difficulties 
for operation.
6.  To increase the reliability of the study, the evaluation 
of all patients for AO and wound healing after surgery 
was performed by one surgeon who was not one of the 
operating surgeons.
The above mentioned cautions were taken to minimize 
standard post‑operative pain on both sides where teeth are 
located. Although it was expected for patients to have similar 
levels of post‑operative pain because of these measures, for the 
2 days that followed surgery some patients whose mandibular 
teeth were treated with ABS reported more pain in the wound 
healing site. VAS values also showed pain in those patients at 
a statistically significant level. As ABS is relatively new and 
no study was conducted on the same issue, it was not possible 
to find any relevant clinical study to consult or utilize. Thus, 
based on the evidence since the occurrence of pain took place 
only in the surgical site that was treated with ABS in some 
patients, it would be safe to deduce that minor excess pain 
may have stemmed from the effect of ABS on the live tissues 
in the wound areas. Further, studies should be conducted on 
this minor discomfort for patients.
There are several discomforting symptoms, such as severe 
pain in the wound site, added cost, extra time, and repeated 
hospital/clinic visits for patients with AO.[2,11,13,22,52,67] In 
the literature, AO is considered to begin within 2‑3 days 
after tooth extractions,[58,68,69] and 95‑100% of AO cases 
have been reported within 1 week.[16] Pain caused by the 
occurrence of AO should not be confused with the pain 
that occurs in the surgical site that was treated with ABS we 
used in our study because the pain caused by AO occurs as 
a strong pain in the second or third day after the operation.
High‑volume surgical irrigation with the physiological serum 
solution may be of benefit in lowering the overall AO rate.[61] 
In our study, control sockets were irrigated with only 1.0 mL 
of physiological serum, the same as the volume of ABS used.
In previous studies, although some materials, such as 
medicated packing,[43] tetracycline‑treated polylactic 
acid,[49] and zinc oxide‑eugenol packing,[70] have been placed 
in removed tooth sockets to reduce the AO incidence, there 
is also evidence of foreign body reactions and unwanted 
side‑effects during the wound‑healing period.[43,49,70] ABS 
administration into the sockets did not induce any foreign 
body reaction or any unwanted side‑effect during the wound 
healing period, apart from post‑operative pain in the first 
2 days after surgery.
Medicated packing material that is placed immediately to 
reduce AO formation in a post‑operative extraction socket 
has some disadvantages in that the medicated packing 
should be removed from the tooth socket and a delay in 
wound closure can occur.[43] ABS administration into the 
sockets does not have these disadvantages.
There are many known hemostatic materials, such as 
medicinal plant extracts (e.g., ABS), oxidized regenerated 
cellulose (Surgicel), polylactic acid granules or mesh, fibrin 
sealants, microfibrillar collagen, gelatin hemostatic agents, 
and cyanoacrylate adhesives.[30,37,48,71,72]
Surgicel is a known biodegradable hemostatic material 
that has been used to provide hemostasis and to control 
bleeding. This material causes hemostasis by a physical 
mechanism at the hemorrhage site.[71] If it is used for 
hemostasis, the removal of Surgicel is advised to prevent 
complications due to a mass effect or a reaction after 
hemostasis has been achieved.[36,73] In a previous clinical 
study, Suleiman[36] reported that the application of Surgicel 
into extraction sockets after removal of mandibular impacted 
third molars increased the incidence of AO. However, our 
data demonstrated that ABS administration into sockets 
for hemostasis after removal of mandibular impacted third 
molars did not increase the incidence of AO. In addition, it 
is not necessary to remove ABS from the hemorrhage site, 
unlike Surgicel.
In another study, Brekke et al.[72] reported that the use of 
polylactic acid mesh as a biodegradable surgical implant 
reduced the incidence of AO following mandibular 
third molar extraction. However, in a later prospective 
randomized clinical study, Hooley and Golden[48] found 
that polylactic acid granules did not reduce the incidence 
of AO; indeed, their use may actually have increased the 
incidence. In this present study, we showed that ABS 
administration into sockets for hemostasis after removal 
of mandibular impacted third molars did not increase the 
incidence of AO.
In summary, the results of this randomized clinical study 
demonstrated that ABS administration into sockets for 
hemostasis after impacted mandibular third molar surgery 
did not increase the incidence of AO. This offers advantages 
for both the surgeon and patient, such as decreasing the 
number of post‑operative visits for AO management. 
Furthermore, ABS administration into sockets for 
hemostasis may increases post‑operative pain, but that is a 
minor discomfort, for the first 2 days after surgery. No other 
discomfort due to its use was reported by these patients. 
Thus, ABS can be used safely for hemostasis after impacted 
mandibular third molar surgery.
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